Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Blood thinner Xarelto now has 11 indications; here’s a look at the latest two

The blood thinner from Janssen generated nearly $6.5 billion in global revenue in 2020.

By Brian Buntz | January 12, 2022

JanssenLast December,’s (NYSE:JNJ) blockbuster blood thinner Xarelto (rivaroxaban) won FDA approval for two new indications for pediatric indications.

The drug now has 11 indications in the U.S., more than any other direct oral anticoagulant (DOAC).

In 2020, the drug generated nearly $6.5 billion in revenue globally.

To learn more about the new indications, we spoke with Dr. James List, global therapeutic area head, cardiovascular, metabolism and retina, Janssen Research and Development, LLC.

Here, Dr. List provides a summary of the new pediatric indications and how the direct-acting anticoagulant (DOAC) compares to rivals.

Drug Discovery & Development: What are the main things prescribing physicians should know about FDA’s approval of two pediatric indications for Xarelto?

Dr. James List

Dr. James List

List: Xarelto (rivaroxaban) is the only DOAC FDA-approved for primary prevention of clots in pediatric patients following the Fontan procedure and the only DOAC in the U.S. to offer an oral suspension formulation for flexible, body weight-adjusted dosing options for pediatric patients. This approval offers healthcare providers, children and their families an alternative to injectable anticoagulants that have long been the standard of care.

Xarelto’s oral suspension formulation and weight-based dosing offer convenience and flexibility for healthcare providers to tailor treatment for pediatric patients. The oral suspension formulation will be administered through a color-coded dosing device designed to help minimize dosing errors. The FDA’s approval of these pediatric indications for Xarelto represents a major advancement in antithrombotic care for pediatric patients.

DDD: Could you briefly summarize how Xarelto stands out from other DOACs and Factor Xa anticoagulants?

List: With this latest approval, Xarelto now has 11 indications — the most of any DOAC — and is the most studied oral Factor Xa inhibitor in its class. Xarelto is the only DOAC in the U.S. to offer an oral suspension formulation for flexible, body weight-adjusted dosing options for pediatric patients and the only DOAC approved for primary prevention of clots in pediatric patients following the Fontan procedure.

DDD: Xarelto is now approved for 11 indications. Can you speak to Xarelto’s expanded versatility since it first hit the market?

List: Xarelto has continued to advance the standard of antithrombotic care across a broad range of patients since its initial approval in the U.S. in 2011.

2021 was a significant year for Xarelto with three new FDA approvals — two pediatric VTE indications and an expanded peripheral artery disease (PAD) indication for Xarelto in combination with aspirin to include patients after lower-extremity revascularization (LER) due to symptomatic PAD. Xarelto is the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation.

Xarelto

Xarelto is offered as an oral suspension formulation for pediatric patients.

The recent FDA approval of two pediatric indications, Xarelto’s 10th and 11th indications, underscores its capability in reducing the risk of blood clots and cardiovascular events in patients from young to old and with a variety of conditions.

DDD: How does Xarelto relate to Janssen’s pledge to serve underserved and vulnerable patients?

List: Pediatric patients are an often under-recognized but especially important patient population. While VTE more commonly occurs in adults, blood clots can still be a serious problem in children — affecting approximately 58 per 10,000 of those hospitalized in the U.S., with rates increasing.

The FDA approval of Xarelto is an advancement in antithrombotic care for those under the age of 18, and the oral suspension formulation and weight-based dosing will provide the convenience and flexibility to tailor treatment to pediatric patients.

With this approval, Janssen is continuing to deliver on its promise to develop new, innovative solutions for underrecognized, vulnerable patient groups and is bold in going where others are not to provide solutions that address unmet need.


Filed Under: Cardiovascular
Tagged With: direct oral anticoagulant, DOAC, Janssen, rivaroxaban, Xarelto
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

BMS
Label update broadens Camzyos reach in obstructive HCM, trims echo burden for stable patients
FDA logo
FDA drug approvals holding steady at 44 YTD in 2024
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
tirzepatide
Lilly, Novo Nordisk battle surge in copycat weight-loss drugs amid safety concerns
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE